Last updated: 2026-09-13 16:39:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Odyssey Therapeutics, Inc. (ODTX) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $24.73, with a market capitalization of $1.18B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $15.10 to $29.05. This page covers its latest market performance, valuation, price trends and company information.
$1.18B | |
$23.94 | |
$29.05 | |
$15.10 | |
$23.64 | |
179.50K | |
256.08K | |
-- | |
$29.05 | |
$15.10 | |
-- | |
-- |
Odyssey Therapeutics, Inc. (ODTX) last closed at $23.64 as of 2026-09-11 23:31:00, unchanged from the previous close of $23.64.
During the latest regular trading session, ODTX traded between $15.10 and $29.05, with a volume of 179.50K shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, Odyssey Therapeutics, Inc. (ODTX) moved from $26.62 to $24.73, representing a decline of 7.10% ($1.89).
The stock traded between $23.50 and $29.05 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 201.89 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 69.0%
ODTX is currently trading at $24.73, placing it 69.0% of the way from its 52-week low of $15.10 to its 52-week high of $29.05. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Odyssey Therapeutics, Inc. (ODTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.